Scholar Rock Holding Corporation $SRRK Stock Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. boosted its holdings in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 164.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 264,695 shares of the company’s stock after purchasing an additional 164,776 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Scholar Rock were worth $12,790,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Squarepoint Ops LLC raised its stake in Scholar Rock by 484.5% during the 2nd quarter. Squarepoint Ops LLC now owns 291,996 shares of the company’s stock valued at $16,060,000 after purchasing an additional 242,041 shares during the last quarter. Nicholas Investment Partners LP bought a new stake in Scholar Rock in the 2nd quarter valued at $4,968,000. Senator Investment Group LP bought a new stake in Scholar Rock in the 2nd quarter valued at $11,275,000. BlackRock Inc. bought a new stake in Scholar Rock in the 2nd quarter valued at $522,175,000. Finally, Legal & General Group Plc acquired a new stake in Scholar Rock in the 2nd quarter worth $3,363,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Down 7.4%

SRRK opened at $43.16 on Friday. Scholar Rock Holding Corporation has a fifty-two week low of $29.35 and a fifty-two week high of $61.76. The company has a debt-to-equity ratio of 1.16, a current ratio of 5.41 and a quick ratio of 7.02. The firm’s fifty day moving average price is $46.38 and its two-hundred day moving average price is $48.22. The company has a market capitalization of $5.27 billion, a P/E ratio of -12.85 and a beta of 0.78.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.30 million. During the same quarter in the prior year, the company posted ($0.90) EPS. On average, analysts anticipate that Scholar Rock Holding Corporation will post -3.11 EPS for the current year.

Latest Scholar Rock News

Here’s some of the latest news about SRRK:

• Positive Sentiment: HC Wainwright raised its Q4 2026 and FY2026 EPS estimates slightly, while maintaining a Buy rating and $70 price target. Scholar Rock analyst estimates
• Negative Sentiment: Wolfe Research cut its rating on SRRK from Outperform to Peer Perform, removing a bullish endorsement and potentially contributing to near-term selling pressure. Wolfe Research ratings
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for FY2027–FY2030, including cutting FY2029 from a profit estimate to a loss and reducing projected FY2030 EPS from $1.44 to $1.00. Those reductions temper the longer-term outlook despite the firm’s Buy rating and $70 target. Scholar Rock analyst estimates

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday. BMO Capital Markets increased their target price on shares of Scholar Rock from $76.00 to $84.00 and gave the company an “outperform” rating in a research note on Monday, September 14th. Barclays downgraded Scholar Rock from an “overweight” rating to a “cautious” rating in a research report on Tuesday, September 15th. Evercore reissued an “outperform” rating and set a $72.00 target price on shares of Scholar Rock in a research report on Tuesday, September 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, October 15th. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Scholar Rock presently has an average rating of “Moderate Buy” and an average price target of $67.67.

Insiders Place Their Bets

In other Scholar Rock news, Director Srinivas Akkaraju bought 146,970 shares of the stock in a transaction that occurred on Monday, October 26th. The shares were acquired at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the purchase, the director directly owned 6,380,517 shares in the company, valued at $265,365,702.03. The trade was a 2.36% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.30% of the stock is currently owned by insiders.

Scholar Rock Company Profile

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.